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ABSTRACT
The receptor for the urokinase-type plasminogen activator (uPAR) is a 
widely recognized master regulator of cell migration and uPAR88–92 is the minimal 
sequence required to induce cell motility and angiogenesis by interacting with the 
formyl peptide receptor type 1 (FPR1). In this study, we present evidence that the 
cyclization of the uPAR88–92 sequence generates a new potent inhibitor of migration, 
and extracellular matrix invasion of human osteosarcoma and chondrosarcoma cells 
expressing comparable levels of FPR1 on cell surface. In vitro, the cyclized peptide 
[SRSRY] prevents formation of capillary-like tubes by endothelial cells co-cultured 
with chondrosarcoma cells and trans-endothelial migration of osteosarcoma and 
chondrosarcoma cells. When chondrosarcoma cells were subcutaneously injected in 
nude mice, tumor size, intra-tumoral microvessel density and circulating tumor cells 
in blood samples collected before the sacrifice, were significantly reduced in animals 
treated daily with i.p-administration of 6 mg/Kg [SRSRY] as compared to animals 
treated with vehicle only. Our findings indicate that [SRSRY] prevents three key 
events occurring during the metastatic process of osteosarcoma and chondrosarcoma 
cells: the extracellular matrix invasion, the formation of a capillary network and the 
entry into bloodstream.
INTRODUCTION
The development of metastases is a multistep 
process that requires active and specifically localized 
extracellular proteolysis as well as the activation of a series 
of physiological and biochemical processes that govern 
the migration from the primary tumor site, the invasion 
through the basement membrane, the entry of metastatic 
cells into the blood vessels and finally localization to 
the second site. Despite significant progress regarding 
potential therapeutic targets aimed at improving survival, 
patients affected by osteosarcoma or chondrosarcoma 
frequently die for systemic spread of the disease, mainly 
to the lungs [1–2]. Thus, elucidating the mechanisms 
controlling metastasis is important for improving outcome 
of patient with osteosarcoma or chondrosarcoma. Both 
diseases are characterized by high neovascularization and 
a high propensity to metastasize through bloodstream [3], 
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but the cellular processes that lead to their interactions 
with endothelium and subsequent invasion through 
endothelial environment are poorly understood. 
The urokinase receptor (uPAR) is emerging as a cell 
surface-associated molecule relevant to cancer invasion 
and metastasis [4–5]. The clinical relevance of uPAR as 
a prognostic marker, when measured in tumor tissues 
and/or plasma, has been demonstrated in various cancer 
diseases, including sarcomas and chondrosarcomas [6–8]. 
Interestingly, it has been documented in a mouse model of 
osteosarcoma that silencing expression of uPAR results in 
a significant reduction of metastasis to lung [9].
The uPAR consists of three domains (D1, D2, and 
D3), anchored to the cell surface through a carboxy-
terminal glycosyl-phosphatidyl-inositol anchor [10]. Full 
uPAR or fragments thereof (deriving from cleavages at 
protease-sensitive regions of the receptor) on cell surface 
may be released in soluble forms in plasma and/or urine. 
When expressed on cell surface, uPAR promotes cell-
associated proteolysis by binding to uPA, which locally 
converts plasminogen into active plasmin, thus favoring 
tissue invasion and metastasis [4–5]. Plasmin generated 
by uPA or uPA itself can cleave intact uPAR (D1D2D3), 
releasing D1. The remaining GPI-anchored D2D3 can be 
left on cell surface or be secreted in the extracellular milieu 
following cleavage of the anchor [11]. Some years ago, 
we found that chondrosarcoma cells produce and release 
in the culture medium soluble forms of uPAR, including 
the intact D1D2D3 and the D2D3 fragment [8]. Ligand-
engaged uPAR also acts as a potent regulator of tumor 
cell migration and matrix attachment, independently of 
its catalytic activity [4–5]. We and others have shown 
that signaling occurs through the assembly of uPAR in 
composite regulatory units with extracellular matrix (ECM) 
proteins such as vitronectin, and with transmembrane 
receptors like the G protein-coupled formyl-peptide 
receptors (FPRs) as well as integrins [12–20].
A crucial signaling region is the protease sensitive 
region linking D1 and D2 domains (uPAR84–95) which 
retains chemotactic activity [15,16]. Its minimal active 
88Ser-Arg-Ser-Arg-Tyr92 sequence is able to trigger cell 
migration and angiogenesis in vitro and in vivo, even in 
the form of synthetic linear Ser-Arg-Ser-Arg-Tyr peptide 
(SRSRY) [17, 21]. Mechanistically, uPAR88–92 sequence 
promotes cell motility by interacting with FPR1 which, 
in turn, triggers vitronectin receptor activation with an 
inside-outside type of mechanism [17]. The X-ray studies 
have shown that the three uPAR domains pack together 
into a concave structure that binds uPA, and that the 
domain boundary between uPAR D1-D2 is more flexible 
than the D2-D3 domain boundary [22–24]. Thus, we 
reasoned that cyclization of the Ser-Arg-Ser-Arg-Tyr 
peptide could reduce conformational flexibility of its linear 
form, thus generating a new, more stable peptide that 
could regulate uPAR88–92-dependent functions. We found 
that both linear SRSRY and cyclized [SRSRY] peptides 
compete with fMLF for binding to FPR type 1 (FPR1). 
However, these peptides exert opposite effect on monocyte 
motility, the linear SRSRY promotes cell migration, while 
the peptide [SRSRY] inhibits cell migration in a dose-
dependent manner, with IC50 value of 0.01 nM. Unlike 
the linear peptide SRSRY, [SRSRY] displays a long-time 
resistance to enzymatic digestion in serum and prevents 
trans-endothelial migration of monocytes [25]. In vivo, 
[SRSRY] reduces intestinal inflammation diminishing 
recruitment of inflammatory monocytes to the inflamed 
tissue [26]. 
In the present study we explored the possibility 
that [SRSRY] may affect trans-endothelial migration of 
osteosarcoma and chondrosarcoma cells. Herein, we show 
that the cyclization of the uPAR88–92 sequence generates 
a potent inhibitor of migration, and extracellular matrix 
invasion of human osteosarcoma and chondrosarcoma 
cells expressing comparable levels of FPR1 on cell 
surface. Interestingly, [SRSRY] inhibits tube formation 
of endothelial cells co-cultured with chondrosarcoma 
cells and trans-endothelial migration of osteosarcoma and 
chondrosarcoma cells. Furthermore, [SRSRY] exerts anti-
metastatic effect reducing in vivo vascular infiltration by 
chondrosarcoma cells.
RESULTS
The peptide [SRSRY] inhibits migration and 
invasion of osteosarcoma and chondrosarcoma 
cells expressing comparable levels of FPR1 
We have recently found that the cyclized peptide 
SRSRY ([SRSRY]) inhibits in a dose-dependent manner 
directional migration of rat basophilic leukemia RBL-
2H3/ETFR cells expressing high levels of constitutively 
activated FPR1. [SRSRY] exerts inhibitory effect by 
preventing uPAR/FPR1 interaction and, consequently, 
agonist-triggered FPR1 activation [25]. To investigate 
whether [SRSRY] affects the motility of osteosarcoma and 
chondrosarcoma cells, cell migration assays were carried 
out in Boyden chambers using two human osteosarcoma 
Saos-2 and MG-63 cell lines and a human chondrosarcoma 
Sarc cell line derived from a primary culture [8]. Saos- 2, 
MG-63 and Sarc cells express low, medium and high 
levels of uPAR, respectively, and comparable levels of 
FPR1 as shown by immunofluorescence (Figure 1A–1B) 
and Western blot analysis (Figure 1C–1D). The peptide 
[SRSRY] failed to trigger migration of all tested cell lines 
when used as chemoattractant at 10 nM concentration 
in Boyden chambers (Figure 1E). However, when the 
uPAR derived linear peptide SRSRY was employed 
to produce the chemotactic gradient, all cell lines were 
able to respond to mitogen stimulus, and the addition of 
equimolar concentration of [SRSRY] (10 nM) reduced 
to the basal level their motility (Figure 1F). These data 
well agree with the notion that the linear peptide SRSRY 
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promotes cell motility by interacting with FPR1 whereas 
its cyclic form inhibits cell migration by preventing 
SRSRY- or fMLF-triggered FPR1 activation [17, 25]. 
They also highlight the involvement of FPR1 in the 
migration ability of osteosarcoma and chondrosarcoma 
cells. To evaluate the effect of [SRSRY] in a system more 
representative of the in vivo context, cells were tested for 
their ability to migrate toward serum which is a source 
of many chemoattractants. Not surprisingly, 10% FBS 
elicited a considerable cell migration of Saos-2, MG-63 
and Sarc cells reaching 248%, 390% and 527% of the 
basal cell migration, respectively. The addition of 10 nM 
[SRSRY] to the lower compartment of Boyden chambers, 
reduced cell migration of Saos-2, MG-63 and Sarc cells by 
45%, 58% and 55%, respectively. These data again agree 
with the comparable expression levels of FPR1 on Saos-2, 
MG-63 and Sarc cells since, despite their different ability 
to migrate toward serum, [SRSRY] reduced by about 50% 
their cell motility (Figure 2A). To further confirm the 
requirement of FPR1 in the [SRSRY] inhibitory effect, a 
subset of cell migration experiments were performed using 
Sarc cells desensitized with 100 nM fMLF as described 
[21]. As expected, desensitized cells failed to move 
towards 10 nM SRSRY or 10 nM fMLF, and retained the 
ability to respond to serum containing chemoattractants, 
although to a minor extent as compared to untreated cells 
(Figure 2B). In all cases, [SRSRY] did not exert inhibitory 
effect on basal as well as on FBS-dependent migration of 
desensitized cells (Figure 2B) and reduced cell migration 
toward SRSRY or 10 nM fMLF to the basal level. All 
together, these findings indicate that [SRSRY] inhibits 
only FPR1-mediated cell motility. 
When cell migration of Sarc cells was monitored 
in real time using the xCELLigence RTCA technology, 
Sarc cells showed a great ability to migrate toward serum 
in agreement with results obtained in Boyden chambers. 
Figure 1: Inhibitory effect of [SRSRY] on migration of FPR1expressing osteosarcoma and chondrosarcoma cells. 
(A–B) Representative images of human osteosarcoma Saos-2 and MG-63 cells, and human chondrosarcoma Sarc cells incubated with 2 
µg/mL R4 anti-uPAR monoclonal antibody (A) or 1:100 anti-FPR1 polyclonal antibody 2 h at 23°C, exposed to Alexa 488-coniugated 
F(ab’)2 fragment of rabbit anti-mouse IgG or goat anti-rabbit IgG for 40 min at 23°C and visualized by a fluorescence inverted microscope. 
Nuclei were stained blue with DAPI. Scale bar: 10 µm. Original magnification: 1000 x. (C–D) Whole cell lysates (20 and 40 µg/sample) 
from Saos-2, MG-63 and Sarc cells were resolved on a 10% SDS-PAGE under unreducing (C) or reducing conditions (D), followed by 
Western blotting with 1 μg/mL R4 anti-uPAR monoclonal antibody (C) or 1 μg/mL anti-FPR1 polyclonal antibody (D) and 0.2 μg/mL anti-
GAPDH polyclonal antibody as loading control. The enclosed bar graphs show the average quantification of the uPAR/GAPDH (C) and 
FPR1/GAPDH (D) content from 3 independent experiments. (E–F) Saos-2, MG-63 and Sarc cells were allowed to migrate for 4 h at 37°C 
in 5% CO2 in Boyden chambers toward DMEM (CTRL), or 10 nM [SRSRY] (E), DMEM (CTRL) or 10 nM SRSRY, in the absence (None) 
or the presence of 10 nM [SRSRY] (F). In all cases, the extent of cell migration was expressed as a percentage of the basal cell migration 
assessed toward serum-free medium, considered as 100% (CTRL). Data are expressed as the mean ± SD of three independent experiments, 
performed in triplicate. ***Statistical significance calculated against the positive control (None) with p < 0.0001. 
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The addition of [SRSRY] reduced their migration in a 
dose-dependent manner (Figure 2C). Slopes representing 
the change rate of cell index generated in the time ranges 
relative to exponential phase curves, revealed that 
inhibition starts in the fM range, it seems to level off in 
the nM range and reaches an overall 50% reduction at 
~100 pM (Figure 2D). Cell migration is a prerequisite 
for cancer invasion. Therefore, we investigated whether 
[SRSRY] prevents matrigel invasion of osteosarcoma 
and chondrosarcoma cells using the xCELLigence RTCA 
technology. Saos-2, MG-63 or Sarc cells re-suspended in 
serum free (CTRL) or growth medium with or without 
10 nM [SRSRY] were seeded on polymerized matrigel. 
Matrigel invasion was monitored in real-time for 18 h 
as cell index changes due to the adhesion of invading 
cells to microelectrodes. As shown in Figure 3, all cell 
Figure 2: Dose-dependent inhibitory effect of [SRSRY] on migration of osteosarcoma and chondrosarcoma cells. 
(A) The indicated cell lines were allowed to migrate toward 10% FBS (None) plus/minus 10 nM [SRSRY] in Boyden chambers for 4 h. (B) 
Sarc cells were exposed to diluents (NT) or desensitized with 100 nM fMLF for 30 min at 37°C and then allowed to migrate toward 10 nM 
fMLF, 10 nM SRSRY or 10% FBS without (None) or with 10 nM [SRSRY] in Boyden chambers for 4 h. In all cases, for quantitative analysis 
of cell migration, the basal value assessed in the absence of chemoattractants (CTRL) was taken as 100% and all values were reported 
relative to that. Data are the means ± SD of three independent experiments, performed in triplicate. Statistical significance calculated 
against None with **p < 0.001; ***p < 0.0001; (C) Migration of Sarc cells monitored in real-time for 12 h as changes in cell index by the 
xCELLigence system. Cells were seeded in CIM-16-well plates and allowed to migrate at 37°C, 5% CO2, toward 10% FBS (None) or 10% 
FBS plus increasing concentration of [SRSRY]. (D) Slopes represent the change rate of cell index generated in a 1–12 h time frame. Data 
represent mean ± SD from a quadruplicate experiment. 
Oncotarget5www.impactjournals.com/oncotarget
lines were able to cross matrigel, although to a different 
extent. [SRSRY] reduced matrigel invasion of Saos-2 (A), 
MG- 63 (B) and Sarc (C) cells, by about 44%, 43% and 
56%, respectively (Figure 3D). 
The peptide [SRSRY] prevents endothelial tube 
formation in a co-culture assay 
We have previously documented that: ì) the 
short Ser88-Arg-Ser-Arg-Tyr92 chemotactic sequence of 
SuPAR stimulates in vitro and in vivo angiogenesis even 
in the form of synthetic linear peptide SRSRY [21]; ìì) 
chondrosarcoma Sarc cells release a large amount of 
SuPAR in the medium [8]; ììì) peptide inhibitors of 
the uPAR/FPR1 interaction inhibit angiogenesis [27]. 
Therefore, we investigated whether Sarc cells promote 
endothelial tube formation in a non-contact co-culture 
system and whether [SRSRY] exerts some effect. Sarc 
cells were grown to confluence and allowed to release 
pro-angiogenic factors in serum free medium for 18 h. 
Then, HUVECs plated on matrigel in an intercup chamber 
were put onto Sarc cells and exposed to their secretion 
products for 4 h. Quantitative analysis of tube formation 
was expressed as a percentage of tubes formed by cord-
like structures exceeding 100 μm in length, counted in 
the presence of serum free medium, considered as 100% 
(CTRL). In the absence of Sarc monolayer, endothelial 
cells failed to form cord-like structures either in the 
absence (CTRL) or in the presence of 10 nM [SRSRY] 
(CTRL+[SRSRY]), (Figure 4A, 4C). Vice-versa, Sarc 
cells stimulated the formation of tube-like structures 
(None) which were reduced almost to basal levels by 
blocking anti-uPAR84–95 polyclonal antibodies [21] but 
not anti α-tubulin antibodies (Figure 4B–4C), indicating 
that the Sarc-triggered proangiogenic effect is mostly 
due to release in the conditioned medium of SuPAR. As a 
result, the addition of 10 nM [SRSRY] reduced endothelial 
capillary-like structures by 67% (Figure 4B–4C). 
The peptide [SRSRY] reduces trans-endothelial 
migration of osteosarcoma and chondrosarcoma 
cells 
The entry of tumor cells into bloodstream is one of 
the earliest events of the metastatic process. To ascertain 
if [SRSRY] prevents adhesion onto endothelium and/or 
trans-endothelial migration of Sarc cells, we performed 
experiments seeding Green Fluorescent Protein (GFP)-
tagged Sarc cells on an endothelial monolayer, labeling 
co-cultures for F-actin and recording images by a confocal 
microscope. Analysis of a single plane confocal to the 
endothelial monolayer revealed numerous Sarc cells 
interacting with HUVECs, that decreased upon addition 
of 10 nM [SRSRY] or anti-uPAR84–95 but not anti α-tubulin 
antibodies (Figure 5A). Z-stack analysis of confocal 
images recorded with 0.25 µm intervals through the entire 
thickness of the endothelial monolayer, revealed that 
the majority of Sarc cells are localized underneath the 
endothelium in the absence of any treatment and that their 
number was not changed by the addition of the indifferent 
anti-α-tubulin Ab (26.8 +/− 4 and 26.2 +/− 6 cells/field, 
respectively). Vice-versa, a 55% and 48% reduction 
of GFP-Sarc cell number was achieved by the addition 
of anti-uPAR84–95 Ab or 10 nM [SRSRY], respectively, 
(Figure 5B). These data suggest that [SRSRY] prevents 
both attachment to endothelium and trans-endothelial 
migration of Sarc cells. To further ascertain if [SRSRY] 
affects trans-endothelial migration of osteosarcoma and 
chondrosarcoma cells, the ability of Saos-2, MG-63 and 
Sarc cells to cross an endothelial monolayer was analyzed 
using the xCELLigence RTCA technology as described 
[28]. HUVECs were allowed to grow until they formed a 
monolayer (~24 h) prior to seeding cells in the presence 
of 10% FBS plus/minus 10 nM [SRSRY]. At this time, 
reduction of impedance values, due to invading cells that 
interrupt monolayer was monitored in real-time for at least 
2 h. An about 15%, 30% and 45% reduction of endothelial 
monolayer integrity was achieved by Saos-2, MG-63 and 
by Sarc cells, respectively, (Figure 5C). The addition 
of 10 nM [SRSRY] inhibited the capability of Saos-2 
(Figure 5D), MG-63 (Figure 5E) and Sarc (Figure 5F) 
cells to cross endothelial monolayers by 47%, 38% and 
25% respectively. All together, these findings indicate that 
[SRSRY], at a 10 nM concentration, prevents in vitro the 
extracellular matrix invasion, the formation of a capillary 
network and the entry into bloodstream. 
The peptide [SRSRY] prevents chondrosarcoma 
growth, intra-tumoral microvessel density and 
release of CTCs in the blood of nude mice
To study the effect of [SRSRY] on tumor growth, 
ten six-eight week old, Foxn1nu/nu female nude mice 
(Harlan) received an injection of human Sarc cells into 
the right flank as a single-cell suspension (1 × 106 cells 
in 100 µl PBS, 96% viability). Five animals received 
i.p-administration of 6 mg/Kg [SRSRY] every day for 
10 days, and five received injections of vehicle only. 
Mice survived to the treatment schedule without clear 
changes in body weight (Figure 6A). Sarc cells readily 
formed tumors when injected subcutaneously in the 
flanks of the immuno-compromised mice (Figure 6B). 
The measurement of tumor volume at various time points 
showed that the kinetics of tumor formation in vehicle-
treated mice were significantly higher than those assessed 
in [SRSRY]-treated mice (Figure 6C). After 10 days, 
tumor volumes of vehicle- and [SRSRY]-treated mice 
were 445+/−285 and 136+/−54 mm3, respectively, with 
p < 0.05. Inhibitory effect of [SRSRY] on tumor growth 
is not due to a reduced proliferation rate, because, 
in vitro, 10 µM peptide did not modify cell growth up to 
92 h (Supplementary Figure S1). However, according with 
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the ability of [SRSRY] to prevent in vitro formation of a 
capillary network (Figure 4), we found that microvessel 
density was reduced in tumors from animals treated with 
[SRSRY] as compared to those treated with vehicle alone 
(Figure 6D and Supplementary Figure S2). Circulating 
Tumor Cells (CTC)s released into the bloodstream from 
solid tumors, are considered markers of the metastatic 
process and [SRSRY] prevents trans-endothelial invasion 
by Sarc cells. Thus, we quantified the CTCs released in 
the blood samples collected just before the sacrifice of 
untreated and treated mice. DNA from nucleated cells 
of murine blood samples was purified and quantitated 
by Real-Time PCR using primers targeting human Alu-
sequences. Number of CTCs was calculated by comparing 
the obtained amplification curves with others generated 
in spiking experiments which were included in every run. 
We found 9,4 +/− 3 CTCs/mL blood samples from 5/5 
untreated mice and 4,8 +/− 2 CTCs/mL blood from 4/5 
mice treated with [SRSRY] (Figure 6E). All together, these 
findings indicate that [SRSRY] prevents three key events 
occurring during the metastatic process of osteosarcoma 
and chondrosarcoma cells: the extracellular matrix 
invasion, the formation of a capillary network and the 
entry into bloodstream. 
Figure 3: Effect of [SRSRY] on matrigel invasion by osteosarcoma and chondrosarcoma cells. (A–C) The indicated cells 
re-suspended in serum-free medium (CTRL) or growth medium without (None) or with 10 nM [SRSRY] were seeded on polymerized 
matrigel in E-16-well plates and allowed to invade matrigel for 18 h. Microelectrodes detect impedance changes which are proportional 
to the number of cells that cross matrigel and are expressed as cell index. Data represent mean ± SD from quadruplicate experiments. 
(D) Slopes represent the change rate of cell index generated in a 1–12 h time frame. 
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DISCUSSION
Beyond the initial acquisition of invasiveness in 
primary tumors, the next major rate-limiting step in the 
metastatic cascade is intra-vasation of tumor cells into 
circulation. Indeed, despite significant progress regarding 
chemotherapy and improvements in the outcome for 
patients with localized osteosarcoma or chondrosarcoma, 
patients who have metastases at diagnosis are not 
uncommon, and still have poor prognosis [1–2, 29]. 
This suggests that, at the time of their initial diagnosis, 
clinically undetectable tumor had already spread to distant 
sites and that an effective systemic anti-metastatic cancer 
therapy is needed. 
In this study, we present evidence that the 
cyclization of the SRSRY sequence of uPAR generates a 
new potent inhibitor of osteosarcoma and chondrosarcoma 
cell invasion. [SRSRY] prevents three key events 
occurring during the metastatic process of osteosarcoma 
and chondrosarcoma cells: the extracellular matrix 
invasion, the formation of a capillary network and the 
entry into bloodstream. When chondrosarcoma cells were 
subcutaneously injected in nude mice, and [SRSRY] 
was daily administered at 6 mg/Kg, it was apparently 
well tolerated as weights of mice injected with vehicle 
or vehicle containing [SRSRY] were comparable. Also, 
we did not notice the occurrence of adverse side effects 
that might hamper the therapeutic potential of [SRSRY]. 
Figure 4: Inhibitory effect of [SRSRY] on tube formation of endothelial cells co-cultured with Sarc cells. Sarc cells were 
grown to confluence and allowed to release pro-angiogenic factors in serum free medium for 18 h. Then, HUVEC plated on matrigel in an 
intercup chamber were layered onto EBM empty well (CTRL) or Sarc cells in the presence or in the absence of 10 nM [SRSRY], 4 μg/mL 
anti-uPAR84-95 Ab or 4 μg/mL anti-α-tubulin control Ab. (A–B) Representative pictures were taken with an inverted microscope. Scale 
bar: 100 µm. Original magnifications: 50×. Dashed boxes enclose areas shown at higher magnification. (C) Quantitative analysis of tube 
formation was calculated as a percentage of tubes formed by cord-like structures exceeding 100 μm in length, counted in the absence of any 
angiogenic stimulus and considered as 100% (CTRL). Data represent means ± SD of three independent experiments performed in duplicate. 
Statistical significance was calculated against None with ***p < 0.0001.
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Moreover, tumor size, intra-tumoral microvessel density 
and circulating tumor cells in blood samples, collected 
before the sacrifice, were significantly reduced in animals 
treated with [SRSRY] as compared to animals treated with 
vehicle only.
The uPAR is a widely recognized master regulator 
of cell migration and plays an important role in sarcoma 
cell invasion [7–9]. However, to date, most therapeutic 
strategies targeting uPAR have not shown robust anti-tumor 
activity [30]. uPAR participates to a complex signaling 
network that control cancer progression, providing a basis 
for the development of new therapies targeting uPAR 
interactors [13]. A possibility is to interfere with the uPAR/
FPR1 interaction. Its uPAR88–92 sequence is the minimal 
region required to induce cell motility and angiogenesis 
by interacting with the formyl peptide receptor type 1 
(FPR1) [17, 21]. Human FPR1, originally identified in 
neutrophils, monocytes and macrophages, elicits many 
responses upon ligation of formyl-peptide ligands derived 
from bacteria and mitochondria, including morphological 
polarization, locomotion, production of reactive-oxygen 
species and release of cytokines and proteolytic enzymes 
[31]. Accumulating evidence demonstrates that FPR1 is 
also involved in the tumor progression of solid tumors 
[32–35]. Therefore, FPR1 is a potential therapeutic 
target for the treatment of malignant human cancer. 
Agonist binding to FPR1 elicits a signal transduction 
cascade involving phosphatidylinositol 3-kinase, protein 
kinase C, AKT and MAPK [35, 36]. Furthermore, it has 
been shown that inhibition of FPR1-triggered ERK1/2 
phosphorylation reduces nuclear translocation of HIF-
1α in glioblastoma cells [34–35]. Being GPI-anchored, 
Figure 5: Inhibitory effect of [SRSRY] on trans-endothelial migration of osteosarcoma and chondrosarcoma cells. (A–B) 
HUVEC were seeded onto matrigel and allowed to attach and to growth for 24 h prior to seeding GFP-Sarc cells suspended in complete 
endothelial medium plus/minus diluents (None), 10 nM [SRSRY], anti-uPAR84-95 Ab or anti-α-tubulin control Ab for 2 h at 37°C, 5% CO2. A. 
Representative images stained with rhodamine- phalloidin and recorded at a single plane confocal to the endothelial monolayer. Scale bar: 
10 µm. Original magnifications: 630x. (B) GFP-Sarc cells were counted on multiple z-series collected at 0.25 µm intervals using a confocal 
microscope (Carl Zeiss). The experiments were performed three times. Statistical significance was calculated against None with **p < 0.001. 
(C) HUVEC suspended in growth medium, were seeded in E-16-well plates and allowed to grow for 20-25 h until they form a confluent 
monolayer (black line), prior to seeding Saos-2 (green line) MG-63 (blue line) or Sarc (red line) cells in growth medium. When HUVECs are 
challenged with crossing cells, there is a drop in electrical resistance which is monitored in real-time for ~2 h as the cell index changes due to 
the rupture of endothelial monolayer. (D–F) With the same experimental design, Saos-2 (D), MG-63 (E), and Sarc (F) cells plus/minus 10 nM 
[SRSRY] were allowed to invade endothelial monolayer. In all cases, data represent mean ± SD from a quadruplicate experiment. 
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and therefore lacking transmembrane and intracellular 
domains, uPAR must cooperate with transmembrane 
receptors to activate intracellular signalling. Upon binding 
to FPR, soluble forms of uPAR containing uPAR84–95 
sequence or the SRSRY peptide promote cell migration 
and angiogenesis by activating vitronectin receptor with 
an inside-out type of mechanism which involves PKC 
and ERK phosphorylation [17, 21]. In the last decade, it 
has been suggested that unengaged uPAR may exist in a 
latent inactive form that, upon binding to urokinase, may 
be subjected to a conformational change shifting the uPAR 
structure to an active conformation [37–38]. We found 
that only the active form of uPAR interacts with FPR1 
thus inducing cell migration and that the substitution of 
Ser90 in the uPAR chemotactic sequence with a glutamic 
acid residue prevents agonist-triggered FPR1 activation 
and internalization leading to the inhibition of uPAR/
vitronectin receptor association and ATF-induced AKT 
phosphorylation [39]. Thus, it is conceivable to hypothesize 
that [SRSRY]-inhibitory effect is mediated by FPR1 which, 
in turn, regulates integrin activity by modulating directly or 
indirectly multiple signaling pathways. 
With the aim to inhibit the functions of uPAR, 
we previously developed a series of linear peptides that 
inhibit uPAR-FPR1 interaction, fMLF-induced FPR1 
internalization and ERK1/2 phosphorylation, reducing 
to the basal level directional cell migration [5, 40–41]. 
However, many of these peptides are unstable to enzymatic 
Figure 6: Inhibitory effect of [SRSRY] on the growth, vascularization and invasion of Sarc cells injected in nude mice. 
Ten six-eight week old, Foxn1nu/nu female nude mice of 23 to 25 g, received an injection of Sarc cells into the right flank as a single-cell 
suspension (1 × 106 cells in 100 µl of sterile PBS, 96% viability). Five animals received i.p. injection of 6 mg/kg peptide [SRSRY] every 
24 h and five received injections of vehicle only (CTRL). After 10 days, mice were anesthetized, subjected to retro-orbital blood collection 
(500 µl/mouse) and then sacrificed by CO2 inhalation. (A) Animals survived to the treatment schedule without clear changes in body weight. 
(B) After sacrifice of untreated (CTRL) and treated [SRSRY] mice, the image of each excised tumor was acquired. (C) Tumor volumes were 
measured by a caliper every 2 days using the formula [length (mm) × width (mm2)/2], where the width and the length are the shortest and the 
longest diameters of each tumor, respectively. (D) Microvessel density was assessed by counting vessels on CD-31 immunostained sections 
in 5 randomly chosen fields per section, in at least two sections per tumor at × 200 magnification. (E) Blood samples were collected from 
mice just before sacrifice and nucleated cells were subjected to DNA extraction and real-time quantitative PCR using primers capable of 
amplifying ALU sequences. Number of CTCs was calculated by spiking experiments included in the run. 
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digestion, which limits their half-life in vivo. In this 
study, we found that osteosarcoma and chondrosarcoma 
cells express comparable levels of FPR1 on cell surface 
and that the peptide [SRSRY] that displays a long-time 
resistance to enzymatic digestion in serum [25], inhibits, 
at 10 nM concentration, both migration and invasion of 
osteosarcoma and chondrosarcoma cell lines exposed 
to growth medium. The mechanism by which the cyclic 
peptide [SRSRY] interferes with fMLF binding to FPR1 
has been investigated in rat basophilic leukaemia RBL-
2H3/ETFR cells expressing high levels of constitutively 
activated FPR1: [SRSRY] inhibits fMLF- induced, FPR1-
mediated cell migration by blocking both internalization 
and fMLF- and SRSRY-uptake of FPR1 [25]. Now we 
found that [SRSRY] at 10 nM concentration reduces to the 
basal level SRSRY-induced cell migration of osteosarcoma 
and chondrosarcoma cell lines. 
The peptide [SRSRY] also reduces the capability 
of osteosarcoma and chondrosarcoma cells to cross 
endothelial monolayers, although to a different extent. 
Extension of blood vessels from preexisting vascular 
structures and de novo formation of vessel networks 
through the recruitment of bone marrow-derived 
precursor cells are the essential process for sustained 
tumor growth and provides the systemic network that 
stimulates metastasis [3]. Here we report that [SRSRY] 
prevents in vitro tube formation by endothelial cells 
exposed to conditioned medium of chondrosarcoma 
cells. According to the finding that Sarc cells express high 
levels of uPAR on cell surface and release a larger amount 
of SuPAR [8], these tube-like structures were reduced 
almost to basal levels by the anti-uPAR84–95 polyclonal 
antibody. However, since chondrosarcoma cells have 
been reported to secrete VEGF [42] and glioblastoma 
cells bearing FPR1 produce VEGF in response to fMLF 
[43], it will be interesting to investigate the possibility 
that [SRSRY] exerts such effect on VEGF-triggered 
angiogenesis. This would not be surprising because 
we have previously reported that inhibitors of uPAR/
FPR1 are able to prevent VEGF-driven angiogenesis 
[27]. Moreover, the decreased vascularization observed 
in tumors formed by Sarc cells implanted in nude mice 
treated with [SRSRY], clearly support the inhibitory 
activity of [SRSRY] on angiogenesis. Indeed, the reduced 
tumor volumes observed in [SRSRY] treated mice cannot 
be due to changes in the proliferation rate since, in vitro, 
[SRSRY] did not modified doubling time of Sarc cells up 
to 10 µM. 
In this context, the peptide [SRSRY] which is 
able to interfere with the ability of osteosarcoma and 
chondrosarcoma cells to cross extracellular matrix, to 
promote formation of a capillary network and to entry into 
bloodstream, could be considered a valid prototype for the 
development of new anti-neoplastic therapies designed to 
counteract metastatic dissemination of osteosarcoma and 
chondrosarcoma cells. 
MATERIALS AND METHODS
Peptide synthesis and purification 
Peptides SRSRY and [SRSRY] were synthesized 
as previously described [25]. Analytical Reversed phase 
HPLC indicated > 95% purity and the correct molecular 
ions were confirmed by liquid chromatography-
electrospray ionization-tandem mass spectrometry. 
Cell lines
Human osteosarcoma Saos-2 and MG-63 cell 
lines  (purchased from ATCC) and chondrosarcoma Sarc 
cells, the last derived from a chondrosarcoma primary 
culture [8], were grown in Dulbecco Modified Eagle 
Medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS), 100 IU/mL penicillin and 50 μg/ mL 
streptomycin. Sarc transfectants, stably expressing 
Green Fluorescent Protein (GFP), were obtained 
using pEGFP-N1 vector (Clontech) and polyfectamin 
transfection reagent (Quiagen). G418-resistant cells 
expressing the highest levels of GFP were isolated 
and amplified. Human umbilical vein endothelial cells 
(HUVEC)s, purchased by Lonza, and employed between 
the third and the seventh passage, were grown in Eagle 
Basal Medium (EBM) supplemented with 4% FBS, 
0.1% gentamicin, 1 µg/mL hydrocortisone, 10 µg/mL 
epidermal growth factor and 12 µg/mL bovine brain 
extract (Cambrex, Bio Science). 
Fluorescence microscopy 
Cells, seeded on glass slides (30%-40% confluence), 
were fixed with 2.5% formaldehyde in PBS for 10 min 
at 4°C, than incubated 2 h at 23°C with 2 μg/mL R4 
anti-uPAR monoclonal antibody or 1:100 anti-FPR1 
polyclonal antibody (Ab), the first kindly provided by G. 
Hoyer-Hansen (Finsen Institute, Copenhagen, Denmark), 
the last purchased from Santa Cruz Biotechnology. 
Immunofluorescence was carried out by incubating 
slides with 1:700 diluted Alexa 488-coniugated F(ab’)2 
fragment of rabbit anti-mouse IgG or goat anti-rabbit IgG 
(Molecular Probes) 40 min at 23°C. After nuclear staining 
with 4–6-diamidino-2-phenylindole dye (DAPI), cells 
were mounted using 20% (w/v) mowiol, and visualized 
with the Axiovert 200M inverted fluorescent microscope 
connected to a video camera (Carl Zeiss). 
Western blotting 
Cells detached using 200 mg/L EDTA, 500 mg/L 
trypsin (Cambrex), were lysed in RIPA buffer (10 mM 
Tris pH 7.5, 140 mM NaCl, 0.1 % SDS, 1% Triton X-100, 
0.5% NP40) containing protease inhibitor mixture. Protein 
content of cell lysates was measured by a colorimetric 
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assay (BioRad). Twenty and forty µicrograms of proteins 
from each cell lysate were separated on 10% SDS-PAGE 
and transferred onto a polyvinylidene fluoride membrane. 
The membranes were blocked with 5% non-fat dry milk 
and probed with 1 μg/mL R4 anti-uPAR monoclonal 
antibody recognizing uPAR D3 domain, 1 μg/mL anti-
FPR1 polyclonal antibody (Abcam), or 0.2 μg/mL 
GAPDH Ab (Santa Cruz Biotechnology). Washed filters 
were incubated with horseradish peroxidase-conjugated 
anti-mouse or anti-rabbit antibody and detected by 
ECL (Amersham- GE Healthcare). Densitometry was 
performed using the NIH Image 1.62 software (Bethesda, 
MD). Each experiment was performed three times.
Cell migration in Boyden chamber 
Cell migration in Boyden chambers was carried 
out as described [17]. Briefly, cell suspension (1 x105 
viable cells/mL serum free medium) was seeded in each 
upper chamber. Lower chambers were filled with DMEM 
alone, DMEM containing 10 nM SRSRY, 10 nM fMLF, 
or 10% FBS with/without 10 nM [SRSRY]. A subset of 
experiments were performed on cells desensitized with 
100 nM fMLF for 30 min at 37°C in humidified air 
with 5% CO2 as described [21]. The two compartments 
were separated by 8 μm pore size polycarbonate filters 
(Neuroprobe) coated with 2.5 µg/mL vitronectin 
(Corning). Incubation, was carried out for 4 h at 37°C 
in humidified air with 5% CO2. At the end of the assay, 
cells on the lower filter surface were fixed with ethanol, 
stained with haematoxylin and 10 random fields/filter 
were counted at 200x magnification. Each experiment was 
performed three times in triplicate.
Migration kinetic of cells monitored in real time
Kinetic of cell migration was monitored in real 
time using the xCELLigence Real Time Cell Analysis 
(RTCA) technology (Acea Bioscience) as described [28]. 
For these experiments we used CIM-16-well plates which 
are provided with interdigitated gold microelectrodes on 
bottom side of a filter membrane interposed between a 
lower and an upper compartment. The lower chamber was 
filled with serum-free medium or growth medium with/
without 10 nM [SRSRY]. Cells (2 × 104 cells/well) were 
seeded on filters in serum-free medium. Microelectrodes 
detect impedance changes which are proportional to the 
number of migrating cells and are expressed as cell index. 
Migration was monitored in real-time for 12 h. Each 
experiment was performed at least twice in quadruplicate.
Invasion kinetic of cells monitored in real time
This assay was performed using E-16-well plates 
and the xCELLigence RTCA technology as described 
[28]. Bottom wells were coated with 20 µg/well matrigel 
diluted in serum free medium. Matrigel was allowed to 
polymerize for 1 h at 37°C prior to seeding cells (1 × 104 
cells/well) suspended in growth medium plus/minus 10 nM 
[SRSRY]. Cells that cross matrigel adhere to the bottom of 
plates causing impedance changes which are proportional 
to the number of invading cells. Matrigel invasion was 
monitored in real-time for 18 h. The impedance value of 
each well was automatically monitored and expressed as 
a cell index value. The experiments were performed three 
times in in quadruplicate. 
Cell proliferation
Cell proliferation of Sarc cells was assessed using 
the xCELLigence technology as described [28]. Briefly, 
cells (2 × 103/well) were seeded in E-16-well plates 
in growth medium and left to growth for 92 h in the 
presence or the absence of 10 µM [SRSRY] or diluents. 
Microelectrodes placed on the bottom of plates, detect 
impedance changes which are proportional to the number 
of adherent cells and are expressed as cell index. Growth 
medium with/without [SRSRY] was replaced every 24 h. 
The experiments were performed twice in quadruplicate.
Tube formation in a non-contact co-culture 
system
Sarc cells were grown to 80% confluence (1.5 × 105 
cells/well) on 24 well plates and kept serum free for 18 h 
prior to the experiment. Growth factor reduced matrigel 
(100 µl/well) (Becton Dickinson, cat. 356230) was 
allowed to polymerize on a polyester membrane in an 
intercup chamber. Subsequently, the intercup chamber was 
introduced in the wells filled with DMEM or conditioned 
medium of Sarc cells. When indicated, 4 µg/ml rabbit 
anti-uPAR84–95 polyclonal antibody, 4 μg/mL α-tubulin 
polyclonal antibody or 10 nM [SRSRY] were added to 
well and kept during the assay. HUVEC (2 × 104 cells/
sample) were seeded on matrigel at 37°C, 5% CO2 for 
4 h. To quantify tube formation five random areas/well 
at 100x magnification were imaged and the number of 
tubes formed by cord-like structures exceeding 100 μm in 
length [21], measured using Axiovision 4.4 software (Carl 
Zeiss), were counted. The experiments were performed 
three times in duplicate.
Trans-endothelial migration 
To assess the ability of Sarc cells to adhere onto and/
or cross endothelium, GFP-tagged Sarc cells were seeded 
on an endothelial monolayer as previously described 
[25]. Briefly, sterile round glass coverslips (12 mm in 
diameter) were coated with 1:8 diluted matrigel (Becton 
Dickinson). HUVEC (5x104 cells in 200 μL/well) were 
seeded onto matrigel and allowed to attach and to growth 
for 24 h at 37°C, 5% CO2 prior to seeding GFP-Sarc cells 
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(1 × 104 cells/well) suspended in complete endothelial 
medium plus/minus diluents, 10 nM [SRSRY], 4 µg/
ml anti-uPAR84–95 or 4 μg/mL anti-α-tubulin antibodies 
for 2 h at 37°C, 5% CO2. Then, slides were fixed and 
permeabilized with 2.5% formaldehyde-0.1% Triton 
X-100 in PBS for 10 min at 4°C, washed in PBS and 
then incubated with 0.1 µg/mL rhodamine-conjugated 
phalloidin (Invitrogen) at 23°C for 45 min. Finally, 
GFP-Sarc cells were identified and counted on multiple 
z-series collected at 0.25 µm intervals using a confocal 
microscope (Carl Zeiss). Trans-endothelial migration 
assays were performed using the xCELLigence RTCA 
technology as described [28]. Briefly, HUVECs (1x104 
cells/well) suspended in growth medium, were seeded in 
E-16-well plates and allowed to grow for ~24 h until they 
form a confluent monolayer, prior to seeding osteosarcoma 
or chondrosarcoma cells (1x104 cells/well) in growth 
medium plus/minus 10 nM [SRSRY]. When HUVECs are 
challenged with crossing cells, there is a drop in electrical 
resistance which is monitored in real-time for 2 h as the 
cell index changes due to crossing of the endothelial 
monolayer. The experiment was performed twice in 
quadruplicate. 
Growth and vascularization of tumors in mice
To evaluate the effect of [SRSRY] on tumor growth 
and vascularization, Sarc cells were injected, as a single-
cell suspension (1 × 106 cells in 100 µl of sterile PBS, 97% 
viability), subcutaneously in the flanks of ten six-eight 
week old, Foxn1nu/nu female nude mice (Harlan). Animals 
were randomized into two groups of five with the treatment 
group receiving 6 mg/kg [SRSRY] by intra-peritoneal 
injection every 24 h and the control group receiving an 
equivalent injected volume of vehicle (PBS) only. Time-
dependent average weight was monitored every two days. 
The length and the width of the tumors were measured at 
different time points with the help of a calliper and the 
volume was calculated using the formula: ½ × (width)2 × 
length (mm). After 10 days, blood samples (at least 500 
µL/mouse) from the retroorbital venous plexus of mice 
anesthetized with 1% isoflurane were collected using a 
heparinized capillary tube and processed for determination 
of the Circulating Tumor Cells (CTC)s. Then, animals 
were sacrificed and the excised tumors were fixed in 
buffered formalin and processed for paraffin sectioning. 
Tumor vascularization was assessed by counting vascular 
channels harbouring red blood cells on CD31 immuno-
stained sections in 5 randomly chosen fields per section, in 
at least two sections per tumor at x 200 as described [28]. 
Isolation and enumeration of CTCs
To quantify CTCs, DNA from nucleated cells of 
murine blood samples (500 μl/mouse) was purified using 
the QIAamp DNA Mini Kit (Qiagen), according to the 
manufacturer›s protocol. Quantitative RT-PCR (7900 HT 
Fast Real-Time PCR System, Applied Biosystems) was 
performed using 18 ng DNA and the SYBR Select Master 
Mix (Applied Biosystems ). Primers targeting human Alu-
sequences [FW 5′- CACCTGTAATCCCAGCACTTT-3′/
RW 5′-CCCAGGCTGGAGTGCAGT-3′] were employed 
to a final concentration of 0.5 μM. The number of CTCs 
was calculated by comparing the obtained CT with 
a standard amplification curve generated in spiking 
experiments (1 to 50 cells were collected by pipetting 
under microscopic control) which were included in every 
run. DNA from murine blood was included as a negative 
control. 
Statistical analysis
The data were analysed for significance using 
Student’s t-test. Differences were considered statistically 
significant at a level of p < 0.05.
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